Lecozotan
Chemical compound
From Wikipedia, the free encyclopedia
Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients.[1] As of June 2008[update], the first Phase III clinical trial has been completed.[2]
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H30ClN5O3 |
| Molar mass | 520.03 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Method of action
Lecozotan is a competitive, selective 5-HT1A receptor antagonist[3] which enhances the potassium-stimulated release of acetylcholine and glutamate.[4]